“WCLC has been proud to participate in the Gift Responsibly Campaign in the past, and we are once again committed to supporting this important initiative in 2024,” said Kevin van Egdom, Director ...

Acalabrutinib and venetoclax, with or without obinutuzumab, improved PFS over chemoimmunotherapy in newly diagnosed CLL patients. The fixed-duration regimen offers potential cost savings and ...

At the World Conference on Lung Cancer (WCLC), Gilead unveiled data from its phase 2 EVOKE-02 study of already-approved TROP2 drug Trodelvy (sacituzumab govitecan), showing what it said was ...

The drugmaker teased the results earlier this year but provided details of the hard data at WCLC, including that the combination reduced the risk of disease progression or death by 38% compared to ...